References
- World Health Organization. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020. Geneva, Switzerland: World Health Organization; 2013.
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;280:2095–2128.
- Maxwell JC. The pain reliever and heroin epidemic in the United States: shifting winds in the perfect storm. J Addict Dis. 2015;34:127–140.
- Botticelli M. Addressing the epidemic of prescription opioid abuse and heroin use. https://www.whitehouse.gov/blog/2016/02/01/preventing-epidemic-opioid-abuse-and-heroin-use. Accessed March 1, 2014.
- Han B, Compton WM, Jones CM, Cai R. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003–2013. JAMA. 2015;314:1468–1478.
- Cheatle M, Comer D, Wunsch M, Skoufalos A, Reddy Y. Treating pain in addicted patients: recommendations from an expert panel. Popul Health Manag. 2014;17:79–89.
- Mars SG, Fessel JN, Bourgois P, Montero F, Karandinos G, Ciccarone D. Heroin-related overdose: the unexplored influences of markets, marketing and source-types in the United States. Soc Sci Med. 2015;140:44–53.
- Cicero TJ, Ellis MS, Harney J. Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med. 2015;373:1789–1790.
- Stinchfield R, Owen P. Hazelden's model of treatment and its outcome. Addict Behav. 1998;23:669–683.
- Jonas DE, Amick HR, Feitner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systemic review and meta-analysis. JAMA. 2014;311:1889–1900.
- Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104:1193–1200.
- Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-nalaxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68:1238–1246.
- Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210–218.
- Galanter M, Dermatis H, Post S, Santucci C. Abstinence from drugs of abuse in community-based members of Narcotics Anonymous. J Stud Alcohol Drugs. 2013;74:349–352.
- Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies: tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–2066.
- Gilman S, Galanter M, Dermatis H. Methadone Anonymous: a 12-step program for methadone maintained heroin addicts. Subst Abus. 2001;22:247–256.
- Monico LB, Gryczynski J, Mitchell SG, Schwartz RP, O'Grady KE, Jaffe JH. Buprenorphine treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. J Subst Abuse Treat. 2015;57:89–95.
- Project Match Research Group. Matching alcoholism treatments to client heterogeneity: Project MATCH post treatment drinking outcomes. J Stud Alcohol. 1997;58:7–29.
- Moos R, Moos B, Andrassy J. Outcomes of four treatment approaches in community residential programs for patients with substance use disorders. Psychiatr Serv. 1999;50:1577–1583.
- Timko C, DeBenedetti A, Billow R. Intensive referral to 12-Step self-help groups and 6-month substance use disorder outcomes. Addiction. 2006;101:678–688.
- Campbell BK, Guydish J, Le T, Wells EA, McCarty D. The relationship of therapeutic alliance and treatment delivery fidelity with treatment retention in a multisite trial of Twelve-Step facilitation. Psychol Addict Behav. 2015;29:106–113.
- Kaskutas LA, Subbaraman MS, Witbrodt J, Zemore SE. Effectiveness of making Alcoholics Anonymous easier: a group format 12-step facilitation approach. J Subst Abuse Treat. 2009;37:228–239.